Bevonescein

PreclinicalSmall molecule

AAlume Biosciences, Inc.

Bevonescein is one of 50 small molecule programs targeting Efficacy. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

EfficacyCompleted

EfficacyPreclinical

Completed

Competition

Competitive Landscape

139 competitors in Efficacy

#DrugCompanyPhaseTrials

Rayos

RRoxane Laboratories

Phase 3

5 2

Paraplatin

AAvyxa

Phase 3

4 3

Lesinurad

EEsperion Therapeutics, Inc.

Phase 3

2 4

Insulin 320

Novo Nordisk

Phase 3

5 5

Endothelin Receptor Antagonist

RRadboud University Medical Center

Phase 3

1 6

Sepofarsen

PProQR Therapeutics

Phase 3

1 7

Veracept

SSebela Women's Health Inc.

Phase 3

1 8

Cetaphil

GGalderma R&D

Phase 3

1 9

Aralen

Sanofi

Preclinical

2 10

Primaquine

Sanofi

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Surgery1 trial

Bevonescein to Highlight Nerves in Patients Undergoing Head & Neck Surgery

Completed·AAlume Biosciences, Inc.·Phase 1/2·NCT04420689·27 enrolled

Nerve Injury1 trial

Multicenter Open-Label Feasibility Study of Intraoperative Nerve and Ureter Visualization With Bevonescein in Patients Undergoing Minimally Invasive Abdominopelvic Surgery

Completed·AAlume Biosciences, Inc.·Phase 2·NCT06662097·27 enrolled

Head and Neck Surgery1 trial

Phase 2/3 Safety and Efficacy Trial of the REVEAL 475 System for Bevonescein-Assisted Intra-Operative Visualization of Nerves in Head and Neck Surgery

Completed·AAlume Biosciences, Inc.·Preclinical·NCT06227585·155 enrolled

Unspecified1 trial

Bevonescein (ALM-488) For Intra-Operative Visualization of Nerves In Head And Neck Surgery

Completed·AAlume Biosciences, Inc.·Phase 3·NCT05377554·154 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Bevonescein. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Bevonescein compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Bevonescein. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Alume Biosciences, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: AAlume Biosciences, Inc.

Bevonescein

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Surgery1 trial

Nerve Injury1 trial

Head and Neck Surgery1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News